Israeli Immune Therapy Shows Safety in First Human Trial for Alzheimer’s

A Phase 1 clinical trial of an Israeli‑developed immune therapy for Alzheimer’s disease reported a favourable safety profile. The investigational antibody, IBC‑Ab002, was created by researchers at the Weizmann Institute of Science in Rehovot, led by Prof. Michal Schwartz. Unlike most current treatments that target amyloid plaques, the therapy aims to restore the brain’s age‑related immune function, modulating neuroinflammation and microglial activity.

The trial, published in Nature Medicine, provided the first human evidence supporting Schwartz’s theory that immune decline contributes to neurodegeneration. Early results showed the drug was well‑tolerated and engaged its intended immune pathways, paving the way for further efficacy studies in later trial phases.